Clinical trials: Coronary Stenosis
Coronary Artery Stenosis
Coronary Laser Atherectomy System for Treatment of Coronary Artery Stenosis (SHINE)
This prospective, multi-center clinical trial evaluates the safety and efficacy of the Coronary Laser Atherectomy System for the pretreatment of coronary artery stenosis.
- Trial name
- SHINE (NCT07697638)
- Testing
- Coronary Laser Atherectomy System, CVX300 Laser System
- Volunteers
- 218 people
- Sponsor
- Shanghai MicroPort Rhythm MedTech Co., Ltd.
Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM)
Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy
The goal of this clinical trial is designed to characterise the safety, tolerability, efficacy, and PK of Aom0304 across oHCM and nHCM populations and to inform dose selection for future Phase 3 development.
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM), Non-obstructive HCM (nHCM)
- Trial name
- NCT07675668
- Testing
- QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID)
- Volunteers
- 56 people
- Sponsor
- Amckaus PTY LTD.
Aortic Valve Stenosis
Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)
Transcatheter Aortic Valve Implantation (TAVI) is now the method of choice to treat aortic stenosis in old and frail patients. Antiplatelet therapy must be associated for the procedure and during few weeks after implantation in…
- Trial name
- TICTAVI (NCT02817789)
- Testing
- Ticagrelor alone, Combination lysine acetylsalicylate - clopidogrel
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Coronary Artery Disease, Coronary Restenosis
Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)
The primary objective of this study is determine the safety and performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter for the treatment of…
- Conditions
- Coronary Artery Disease, Coronary Restenosis, Coronary Atherosclerosis, Coronary Arteriosclerosis
- Trial name
- AGENT-ISR (NCT02151812)
- Testing
- Agent Paclitaxel-coated balloon, SeQuent® Please Paclitaxel-coated Balloon
- Where
- 12 sites in France, Germany
- Volunteers
- 123 people
- Sponsor
- Hemoteq AG
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician…
- Trial name
- SPARC-HCM (NCT07557498)
- Testing
- Mavacamten
- Where
- United Kingdom
- Volunteers
- 362 people
- Sponsor
- Bristol-Myers Squibb
Aortic Stenosis
Study of Platelet Activation by Severe Aortic Stenosis and Its Correction by Transcatheter Aortic Valve Implantation
Study of platelet activation by severe aortic stenosis and its correction by Transcatheter Aortic Valve Implantation (TAVI)
- Trial name
- TAVI (NCT02504632)
- Testing
- test, control group
- Where
- France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Toulouse
Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Federated Learning Implementation Platform
HCM FLIP study is a two-phase protocol focusing on the detection of Hypertrophic Cardiomyopathy using Electrocardiograms and Echocardiograms through Federated Learning.
- Trial name
- HCM FLIP (NCT06461468)
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- American Heart Association
Aortic Stenosis
TAVI Without On-Site Cardiac Surgery in Poland: A Randomized Multicenter Trial Protocol
Aortic stenosis (AS) represents the most prevalent acquired valvular heart disease in European populations, and transcatheter aortic valve implantation (TAVI) has become the dominant treatment modality for patients with…
- Trial name
- NOSCAR-TAVI (NCT07515768)
- Testing
- transcathter aortic valve implantation
- Volunteers
- 404 people
- Sponsor
- Medical University of Warsaw
Aortic Stenosis, Cardiogenic Shock
Transcatheter AortiC Valve Implantation in aorTic stenosIs CardiogenIc Shock
The goal of this clinical trial is to learn if acute transcatheter aortic valve implantation (TAVI) is superior to standard treatment (stabilization in an intensive care unit and TAVI subsequently) to treat cardiogenic shock in…
- Trial name
- TACTICS (NCT06638268)
- Testing
- Acute TAVI, Stabilization and subacute TAVI
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Myocardial Infarction, Myocardial Ischemia
18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability
This study is designed as a prospective observational feasibility study. The investigators will study whether vulnerable plaques on OCT (fibrous cap ≤ 70 μm) show a locally increased uptake of 18F-choline on PET-MRI compared to…
- Conditions
- Myocardial Infarction, Myocardial Ischemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT03252990
- Testing
- PET-MRI, Optical Coherence Tomography
- Where
- Netherlands
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Coronary Artery Disease, Coronary Artery Stenosis
ABSORB III Randomized Controlled Trial (RCT)
The ABSORB III RCT is a prospective randomized, single-blind, multi-center trial. It is the pivotal trial to support the US pre-market approval (PMA) of Absorb™ Bioresorbable Vascular Scaffold (BVS).
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Trial name
- ABSORB-III (NCT01751906)
- Testing
- Absorb BVS, XIENCE
- Where
- 192 sites in United States, Australia
- Volunteers
- 2,008 people
- Sponsor
- Abbott Medical Devices
Aortic Valve Stenosis
Safety and Feasibility of Early Discharge for Transfemoral Transcatheter Aortic Valve Replacement
The primary objective of this study is to determine the efficacy, safety and feasibility of next day discharge home in patients undergoing self-expandable transfemoral TAVR utilizing the Vancouver 3M Clinical Pathway.
- Trial name
- SAFETAVR (NCT03600935)
- Testing
- Vancouver Clinical Pathway
- Volunteers
- 315 people
- Sponsor
- BC Centre for Improved Cardiovascular Health
Valve Heart Disease, Aortic Stenosis
Comparative Imaging Assessment of Valvular Heart Disease
The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right…
- Conditions
- Valve Heart Disease, Aortic Stenosis, Aortic Regurgitation
- Trial name
- NCT04126018
- Testing
- MRI with strain measurement, Echocardiography
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- The Cleveland Clinic
Aortic Stenosis, Aortic Regurgitation
Mitroflow DL Post Approval Study- North America
Prospective, non-randomized, multicenter post-approval study to collect long term clinical and echographic data on Mitroflow DL patients.
- Conditions
- Aortic Stenosis, Aortic Regurgitation, Aortic Valve Insufficiency, Heart Valve Diseases
- Trial name
- NCT02351726
- Testing
- Mitroflow DL
- Where
- 13 sites in United States
- Volunteers
- 186 people
- Sponsor
- LivaNova
Aortic Stenosis
PARTNER II Trial: S3iCAP
Following completion of enrollment in the PARTNER II SAPIEN 3 intermediate risk trial, this trial provided continued access to treatment for subjects with severe aortic stenosis who were at intermediate surgical risk.
- Trial name
- PII S3i CAP (NCT02687035)
- Testing
- SAPIEN S3 valve
- Where
- 56 sites in United States, Canada
- Volunteers
- 1,822 people
- Sponsor
- Edwards Lifesciences
Coronary Artery Disease, Coronary Stent Restenosis
A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis
The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure.
- Trial name
- NCT00244647
- Testing
- RESTEN-MP
- Volunteers
- 40 people
- Sponsor
- Sarepta Therapeutics, Inc.
Heart Failure, Aortic Stenosis
Heart Failure and Aortic Stenosis Transcriptome
This study is aimed to investigate the global transcriptome in order to determine the expression profile of messenger RNAs (mRNAs), as well as long noncoding- (lncRNAs) and micro noncoding-RNAs (miRNAs) in heart failure (HF) and…
- Trial name
- RNA-HF-AS (NCT03268135)
- Testing
- measurement of RNAs
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- IRCCS Policlinico S. Donato
Heart Valve Diseases, Aortic Valve Stenosis
Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice
Valvular heart disease (VHD) is a growing public health concern globally, with increasing disease burden and rising interest in advanced treatment strategies such as transcatheter interventions.
- Conditions
- Heart Valve Diseases, Aortic Valve Stenosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency
- Trial name
- NCT07068633
- Where
- 2 sites in South Korea
- Volunteers
- 30,000 people
- Sponsor
- Yonsei University
Cardiomyopathy, Hypertrophic
A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).
- Trial name
- ODYSSEY-HCM (NCT05582395)
- Testing
- Mavacamten
- Where
- 224 sites in United States, Australia and 21 more
- Volunteers
- 580 people
- Sponsor
- Bristol-Myers Squibb
Myocardial Perfusion Imaging, Diagnostic Certainty
Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis
Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.
- Conditions
- Myocardial Perfusion Imaging, Diagnostic Certainty, Stable Coronary Artery Disease
- Trial name
- NCT07187895
- Testing
- XTR004
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Sinotau Pharmaceutical Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.